Noradrenaline (Norepinephrine) Laboratoire Aguettant (Noradrenaline Tartrate)

Norepinephrine works by directly stimulating alpha‑1 adrenergic receptors, causing powerful vasoconstriction that increases systemic vascular resistance and arterial pressure. It also activates beta‑1 receptors in the heart, enhancing contractility and heart rate, which together improve cardiac output and tissue perfusion during shock states.

The dose of Noradrenaline is individualized and set by the prescribing clinician. It is typically prepared as an intravenous infusion and titrated to achieve target blood pressure and perfusion goals, with adjustments made based on the patient’s response and clinical condition.

Safety data for Noradrenaline in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Noradrenaline, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Noradrenaline is often preferred for septic and distributive shock because it provides strong alpha‑1 mediated vasoconstriction with modest beta‑1 activity, balancing blood pressure support and cardiac output. Compared with phenylephrine, it has less pure vasoconstriction and more inotropic effect; compared with epinephrine, it causes less tachycardia and metabolic disturbance.

Noradrenaline injection should be stored at 2‑8 °C, protected from light, and never frozen. The vial must be kept in its original packaging, and the solution should be inspected for particulate matter before use. Do not shake vigorously; gently invert if mixing is required.

Noradrenaline is given as an intravenous infusion, usually diluted in a compatible carrier solution such as 5% dextrose or normal saline. Administration is performed by qualified medical staff, with continuous monitoring of blood pressure, heart rate and cardiac rhythm to allow rapid titration to the desired therapeutic effect.

The most serious risks include severe hypertension, myocardial ischemia, life‑threatening arrhythmias, tissue necrosis at the infusion site, and pulmonary edema. Prompt recognition of these events and immediate adjustment or discontinuation of the infusion are essential to prevent irreversible damage.

Noradrenaline should be avoided in patients with known hypersensitivity to the drug or its excipients, uncontrolled hypertension, severe peripheral vascular disease where further vasoconstriction could cause ischemia, and in individuals where alternative therapies are more appropriate based on clinical judgment.